HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Dr Chris Baldwin as Chief Executive Officer and Managing Director, effective 5 January 2026.
Read article +HaemaLogiX Ltd, a clinical stage Australian biotech company developing novel immunotherapies for patients with blood cancers (HaemaLogiX), provides the following personnel update.
Read article +HaemaLogiX was pleased to attend the prestigious International Myeloma Society (IMS) Annual Meeting & Exposition, held last week from 14 – 17 September, 2025 in Toronto, Canada.
Read article +HaemaLogiX was honoured to be awarded the “Most Promising CAR-T Pipeline in APAC” at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night.
Read article +HaemalogiX CEO Damian Clarke-Bruce presented at the 19th Bioshares Biotech Summit in Hobart, showcasing the company’s pioneering immunotherapies for multiple myeloma and B-cell disorders.
Read article +